Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGMT | P16455 | 7/20 | 0.70 |
| ▸ | CDK1 | P06493 | 15/20 | 0.62 |
| ▸ | CCNB1 | P14635 | 15/20 | 0.62 |
| ▸ | CCNA2 | P20248 | 14/20 | 0.62 |
| ▸ | CDK2 | P24941 | 14/20 | 0.62 |
| ▸ | CCNA1 | P78396 | 14/20 | 0.62 |
| ▸ | PIN1 | Q13526 | 2/20 | 0.57 |
| ▸ | DPP4 | P27487 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2930276 | 0.79 | CDK1 (0.62) | MGMTCDK1CCNB1CCNA2CDK2 | |
| Methylguanine SCHEMBL231097 | 0.79 | CDK1 (0.69) | MGMTCDK1CCNB1CCNA2CDK2 | |
| Methylguanine SCHEMBL29903462 | 0.79 | CDK1 (0.69) | MGMTCDK1CCNB1CCNA2CDK2 | |
| SCHEMBL8619367 | 0.77 | CDK1 (0.66) | MGMTCDK1CCNB1CCNA2CDK2 | |
| SCHEMBL7983290 | 0.77 | CDK1 (1.00) | MGMTCDK1CCNB1CCNA2CDK2 | |
| SCHEMBL5201806 | 0.76 | CDK1 (0.65) | MGMTCDK1CCNB1CCNA2CDK2 | |
| SCHEMBL8618498 | 0.76 | CDK1 (0.77) | MGMTCDK1CCNB1CCNA2CDK2 | |
| SCHEMBL2938609 | 0.76 | PDPK1 (0.62) | MGMTCDK1CDK2 | |
| SCHEMBL30176198 | 0.76 | CDK1 (0.77) | MGMTCDK1CCNB1CCNA2CDK2 | |
| SCHEMBL9804043 | 0.76 | CDK1 (0.55) | MGMTCDK1CCNB1CCNA2CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5817799-A | 2'-Fluorofuranosyl derivatives and methods for preparing 2'-fluoropyrimidine and 2'-fluoropurine nucleosides | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1998-10-06 | — | — | US | claimed |
| EP-0540686-B1 | 2'-FLUOROFURANOSYL DERIVATIVES AND NOVEL METHOD OF PREPARING 2'-FLUOROPYRIMIDINE AND 2'-FLUOROPURINE NUCLEOSIDES | US COMMERCE (US) | 1995-08-30 | — | — | EP | claimed |
| EP-0540686-A4 | 2'-FLUOROFURANOSYL DERIVATIVES AND NOVEL METHOD OF PREPARING 2'-FLUOROPYRIMIDINE AND 2'-FLUOROPURINE NUCLEOSIDES | US COMMERCE (US) | 1993-05-26 | — | — | EP | claimed |
| EP-0540686-A1 | 2'-FLUOROFURANOSYL DERIVATIVES AND NOVEL METHOD OF PREPARING 2'-FLUOROPYRIMIDINE AND 2'-FLUOROPURINE NUCLEOSIDES. | US COMMERCE (US) | 1993-05-12 | — | — | EP | claimed |
| WO-1992001700-A1 | 2'-FLUOROFURANOSYL DERIVATIVES AND NOVEL METHOD OF PREPARING 2'-FLUOROPYRIMIDINE AND 2'-FLUOROPURINE NUCLEOSIDES | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, U.S. DEPARTMENT OF COMMERCE (US) | 1992-02-06 | — | — | WO | claimed |
| US-10758557-B2 | Methods and compositions for treating hepatitis C virus | IDENIX PHARMACEUTICALS LLC (US) | 2020-09-01 | — | — | US | disclosed |
| US-20190290670-A1 | METHODS AND COMPOSITIONS FOR TREATING HEPATITIS C VIRUS | IDENIX PHARMACEUTICALS LLC (US) | 2019-09-26 | — | — | US | disclosed |
| US-10363265-B2 | Methods and compositions for treating hepatitis C virus | IDENIX PHARMACEUTICALS LLC (US) | 2019-07-30 | — | — | US | disclosed |
| US-20180235993-A1 | METHODS AND COMPOSITIONS FOR TREATING FLAVIVIRUSES AND PESTIVIRUSES | IDENIX PHARMACEUTICALS LLC (US) | 2018-08-23 | — | — | US | disclosed |
| US-9968628-B2 | Methods and compositions for treating flaviviruses and pestiviruses | IDENIX PHARMACEUTICALS LLC (US) | 2018-05-15 | — | — | US | disclosed |
| EP-1292603-B1 | METHODS AND COMPOSITIONS FOR TREATING HEPATITIS C VIRUS | IDENIX PHARMACEUTICALS LLC (US) | 2017-02-22 | — | — | EP | disclosed |
| EP-1736478-B1 | Methods and compositions for treating flaviviruses and pestiviruses | IDENIX PHARMACEUTICALS INC (US) | 2015-07-22 | — | — | EP | disclosed |
| EP-1178051-A2 | PROCESS FOR SELECTIVELY PRODUCING 1-PHOSPHORYLATED SUGAR DERIVATIVE ANOMER AND PROCESS FOR PRODUCING NUCLEOSIDE | Mitsui Chemicals, Inc. (JP) | 2002-02-06 | — | — | EP | disclosed |
| EP-1177201-A1 | 4'-C-ETHYNYL PYRIMIDINE NUCLEOSIDES | YAMASA CORPORATION (JP) | 2002-02-06 | — | — | EP | disclosed |
| US-6333315-B1 | FOR THERAPY OF AIDS(ACQUIRE IMMUNODEFICIENCY SYNDROME) | YAMASA CORPORATION (JP) | 2001-12-25 | — | — | US | disclosed |
| US-6291670-B1 | VIRICIDES AGAINST HUMAN IMMUNODEFICIENCY VIRUS AND AIDS (ACQUIRED IMMUNE DEFICIENCY SYNDROME) | YAMASA CORPORATION (JP) | 2001-09-18 | — | — | US | disclosed |
| WO-2000069876-A1 | 4'-C-ETHYNYL PYRIMIDINE NUCLEOSIDES | YAMASA CORPORATION (JP) | 2000-11-23 | — | — | WO | disclosed |
| WO-2000069877-A1 | 4'-C-ETHYNYL PURINE NUCLEOSIDES | YAMASA CORPORATION (JP) | 2000-11-23 | — | — | WO | disclosed |
| US-6103707-A | TREATMENT OF HERPES SIMPLEX VIRUS 1 (HSV-1), HERPES SIMPLEX VIRUS 2 (HSV-2), HUMAN CYTOMEGALOVIRUS (HCMV) AND VARICELLA-ZOSTER VIRUS | YAMASA CORPORATION (JP) | 2000-08-15 | — | — | US | disclosed |
| EP-0839813-A1 | 9-(2-DEOXY-2-FLUORO-4-THIO-BETA-D-ARABINOFURANOSYL)PURINE DERIVATIVES | YAMASA CORPORATION (JP) | 1998-05-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180235993-A1 | METHODS AND COMPOSITIONS FOR TREATING FLAVIVIRUSES AND PESTIVIRUSES | MTAP, PHOSPHO1, PNP | MGMT 367/4885CDK1 3904/4885CCNB1 3800/4885 |
| US-10758557-B2 | Methods and compositions for treating hepatitis C virus | HAVCR2, HCCS, PYGL | MGMT 148/4885CDK1 3192/4885CCNB1 2336/4885 |
| US-20190290670-A1 | METHODS AND COMPOSITIONS FOR TREATING HEPATITIS C VIRUS | HAVCR2, HCCS, PYGL | MGMT 148/4885CDK1 3192/4885CCNB1 2336/4885 |
| US-10363265-B2 | Methods and compositions for treating hepatitis C virus | HAVCR2, HCCS, PYGL | MGMT 148/4885CDK1 3192/4885CCNB1 2336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.